Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The firs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wenxiao Jiang, Guiqing Cai, Peter Hu, Yue Wang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Non-small cell lung cancer Personalized medicine Pharmacogenomics Pharmacogenetics Drug resistance Vinca alkaloids Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/8201e3885f3f42649a3d9af8a4a8c852
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8201e3885f3f42649a3d9af8a4a8c852
record_format	dspace
spelling	oai:doaj.org-article:8201e3885f3f42649a3d9af8a4a8c8522021-12-02T05:01:19ZPersonalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer2211-383510.1016/j.apsb.2021.02.003https://doaj.org/article/8201e3885f3f42649a3d9af8a4a8c8522021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2211383521000423https://doaj.org/toc/2211-3835Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable patients. With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific oncogenic mutations, but other drugs that target mechanisms universal to all cancers do not. In this review, we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors (i.e., alkylating agents and topoisomerase inhibitors) and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors.Wenxiao JiangGuiqing CaiPeter HuYue WangElsevierarticleNon-small cell lung cancerPersonalized medicinePharmacogenomicsPharmacogeneticsDrug resistanceVinca alkaloidsTherapeutics. PharmacologyRM1-950ENActa Pharmaceutica Sinica B, Vol 11, Iss 11, Pp 3406-3416 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-small cell lung cancer Personalized medicine Pharmacogenomics Pharmacogenetics Drug resistance Vinca alkaloids Therapeutics. Pharmacology RM1-950
spellingShingle	Non-small cell lung cancer Personalized medicine Pharmacogenomics Pharmacogenetics Drug resistance Vinca alkaloids Therapeutics. Pharmacology RM1-950 Wenxiao Jiang Guiqing Cai Peter Hu Yue Wang Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
description	Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable patients. With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific oncogenic mutations, but other drugs that target mechanisms universal to all cancers do not. In this review, we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors (i.e., alkylating agents and topoisomerase inhibitors) and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors.
format	article
author	Wenxiao Jiang Guiqing Cai Peter Hu Yue Wang
author_facet	Wenxiao Jiang Guiqing Cai Peter Hu Yue Wang
author_sort	Wenxiao Jiang
title	Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
title_short	Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
title_full	Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
title_fullStr	Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
title_full_unstemmed	Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
title_sort	personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/8201e3885f3f42649a3d9af8a4a8c852
work_keys_str_mv	AT wenxiaojiang personalizedmedicineofnongenespecificchemotherapiesfornonsmallcelllungcancer AT guiqingcai personalizedmedicineofnongenespecificchemotherapiesfornonsmallcelllungcancer AT peterhu personalizedmedicineofnongenespecificchemotherapiesfornonsmallcelllungcancer AT yuewang personalizedmedicineofnongenespecificchemotherapiesfornonsmallcelllungcancer
_version_	1718400840024195072

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Ejemplares similares